IMbrave150: Atezolizumab plus Bevacizumab in HCC: Efficacy Data and Clinical Practice Implications

home / between-the-lines / imbrave150-atezolizumab-plus-bevacizumab-in-hcc-efficacy-data-and-clinical-practice-implications

Rahul Gosain, MD; Rohit Gosain, MD, and Daniel Ahn, DO, analyze pivotal studies in hepatocellular carcinoma, including HIMALAYA, IMbrave 150, and CheckMate 9DW, discussing study designs, outcomes, patient characteristics, and efficacy data.

EP. 1: IMbrave 150: Overview

Daniel Ahn, DO;Rahul Gosain, MD;Rohit Gosain, MD

September 2nd 2024

Medical experts specializing in hepatocellular carcinoma (HCC) provide a detailed analysis of the IMbrave 150 study design.

EP. 2: IMbrave 150: Patient Characteristics

Daniel Ahn, DO;Rahul Gosain, MD;Rohit Gosain, MD

September 2nd 2024

The panel analyzes how patient characteristics from the IMbrave 150 trial compare to those in other hepatocellular carcinoma studies.

EP. 3: IMbrave 150: Updated Outcomes

Daniel Ahn, DO;Rahul Gosain, MD;Rohit Gosain, MD

September 9th 2024

The panel presents the latest safety and efficacy updates from the IMbrave 150 trial.

EP. 4: Using Atezolizumab + Bevacizumab in Practice

Daniel Ahn, DO;Rahul Gosain, MD;Rohit Gosain, MD

September 9th 2024

Key opinion leaders share their impressions of the IMBrave150 trial data and discuss their real-world clinical experiences using atezolizumab plus bevacizumab in practice.

EP. 5: Vp4 and Baseline Varices Data in IMbrave 150: Clinical Implications

Daniel Ahn, DO;Rahul Gosain, MD;Rohit Gosain, MD

September 16th 2024

Medical experts analyze the exploratory efficacy and safety results for patients with portal vein invasion (Vp4), addressing the challenges in treating this subgroup.

EP. 6: AE Management with Atezolizumab + Bevacizumab

Daniel Ahn, DO;Rahul Gosain, MD;Rohit Gosain, MD

September 16th 2024

Key opinion leaders examine IMbrave 150 data stratified by baseline varices and compare outcomes between patients with Child-Pugh A and B.